BNTC
Benitec Biopharma Inc. [BNTC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BNTC Stock Summary
In the News
BNTC Financial details
Company Rating
-
Market Cap
14.26M
Income
-21.87M
Revenue
61K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.34
Forward P/E
-
PEG
0.05
P/S
108.73
P/B
0.31
P/C
-
P/FCF
-0.44
Quick Ratio
5.72
Current Ratio
5.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-10.94
EPS next Y
-
EPS next Q
-
EPS this Y
-63.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-63.33%
Revenue Q/Q
-
EPS Q/Q
-4.35%
-
-
-
-
SMA20
1.97%
SMA50
5.74%
SMA100
23.27%
Inst Own
-
Inst Trans
-
ROA
-75%
ROE
-224%
ROC
-0.9%
Gross Margin
241%
Oper. Margin
-27167%
Profit Margin
-27049%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.86-9.01
52W High
+25.56%
52W Low
+1030%
RSI
52.38
Rel Volume
0.93
Avg Volume
17.39K
Volume
16.1K
Perf Week
8.65%
Perf Month
1.44%
Perf Quarter
25.42%
Perf Half Y
26.12%
-
-
-
-
Beta
1.024
-
-
Volatility
0.64%, 0.52%
Prev Close
-2.33%
Price
11.3
Change
1.8%
Company Profile
- Volume Average 17.39K
- Market Capitalization 14.26M
- Employee 16
- CEO Dr. Jerel A. Banks M.D., Ph.D.
- Headquarters Hayward,CA,US
- IPO Date 2014-06-24
-
Website
https://benitec.com 
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
